AI-generated summary
The authors report a case series of five patients with mild to moderately severe dementia or possible Alzheimer's disease who received 12 weeks of near-infrared photobiomodulation using 810 nm light. Cognitive scores on the MMSE and ADAS-cog improved significantly, and the authors note that the sample was small and that larger controlled studies are warranted.
- Participants
- 5
- Who or what was studied
- Five patients with mild to moderately severe dementia or possible Alzheimer's disease (MMSE baseline 10-24)
- Wavelengths
- 810 nm
- Limits stated in the abstract
- The abstract notes a small case series with no controls, and the authors state that larger, controlled studies are warranted.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objective
This study investigated whether patients with mild to moderately severe dementia or possible Alzheimer's disease (AD) with Mini-Mental State Exam (MMSE) Baseline scores of 10-24 would improve when treated with near-infrared photobiomodulation (PBM) therapy.
Background
Animal studies have presented the potential of PBM for AD. Dysregulation of the brain's default mode network (DMN) has been associated with AD, presenting the DMN as an identifiable target for PBM.
Materials And Methods
The study used 810 nm, 10 Hz pulsed, light-emitting diode devices combining transcranial plus intranasal PBM to treat the cortical nodes of the DMN (bilateral mesial prefrontal cortex, precuneus/posterior cingulate cortex, angular gyrus, and hippocampus). Five patients with mild to moderately severe cognitive impairment were entered into 12 weeks of active treatment as well as a follow-up no-treatment, 4-week period. Patients were assessed with the MMSE and Alzheimer's Disease Assessment Scale (ADAS-cog) tests. The protocol involved weekly, in-clinic use of a transcranial-intranasal PBM device; and daily at-home use of an intranasal-only device.
Results
There was significant improvement after 12 weeks of PBM (MMSE, p < 0.003; ADAS-cog, p < 0.023). Increased function, better sleep, fewer angry outbursts, less anxiety, and wandering were reported post-PBM. There were no negative side effects. Precipitous declines were observed during the follow-up no-treatment, 4-week period. This is the first completed PBM case series to report significant, cognitive improvement in mild to moderately severe dementia and possible AD cases.
Conclusions
Results suggest that larger, controlled studies are warranted. PBM shows potential for home treatment of patients with dementia and AD.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Dementia, Intranasal photobiomodulation, Light-emitting diode, Near-infrared, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.